Phase 3 Psoriasis Trial, Recruiting (NCT07511647)

Phase 3 Psoriasis Trial, Recruiting NCT07511647 Sponsor: Qilu Pharmaceutical Co., Ltd. Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07511647 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with plaque psoriasis (with or without joint inflammation related to psoriasis) before the study treatment begins
At least 10% of your total body surface area is affected by psoriasis at both your screening and baseline appointments
Your psoriasis severity score (measuring how much of your skin is affected and how severe it is) is 12 or higher at both your screening and baseline appointments
A doctor has rated your psoriasis as moderately severe or worse at both your screening and baseline appointments
You are considered a suitable candidate for light therapy or systemic (whole-body) medication to treat your plaque psoriasis

Who may not be able to join:

You have a type of psoriasis other than plaque psoriasis, such as the kind that causes widespread redness, small teardrop-shaped patches, or pus-filled spots
Your psoriasis was caused or made worse by a medication you are currently taking, such as beta blockers, calcium channel blockers, or lithium

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-36803000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07511647

Sponsor: Qilu Pharmaceutical Co., Ltd.

Phase: Phase 3

Status: Recruiting

Condition: Psoriasis

Trial contact: 021-36803000

More information: https://clinicaltrials.gov/study/NCT07511647

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with plaque psoriasis (with or without joint inflammation related to psoriasis) before the study treatment begins
At least 10% of your total body surface area is affected by psoriasis at both your screening and baseline appointments
Your psoriasis severity score (measuring how much of your skin is affected and how severe it is) is 12 or higher at both your screening and baseline appointments
A doctor has rated your psoriasis as moderately severe or worse at both your screening and baseline appointments
You are considered a suitable candidate for light therapy or systemic (whole-body) medication to treat your plaque psoriasis

Who may not be able to join:

You have a type of psoriasis other than plaque psoriasis, such as the kind that causes widespread redness, small teardrop-shaped patches, or pus-filled spots
Your psoriasis was caused or made worse by a medication you are currently taking, such as beta blockers, calcium channel blockers, or lithium

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Qilu Pharmaceutical Co., Ltd.

Registry

ClinicalTrials.gov

Start date

15 June 2026

Est. completion

30 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients achieving PASI-75 at week 16.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov